SCHEMBL4484518

SCHEMBL4484518

O=C(Nc1ccc(F)cc1F)c1cc(Br)cnc1Cl

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.57
KDM4E B2RXH2 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TAS1R3 Q7RTX0 1/20 0.54
TAS1R1 Q7RTX1 1/20 0.54
TAS1R2 Q8TE23 1/20 0.54
GAA P10253 1/20 0.50
MET P08581 2/20 0.49
NPC1 O15118 3/20 0.49
ALDH1A1 P00352 1/20 0.49
THRB P10828 1/20 0.49
RAB9A P51151 3/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TSHR P16473 1/20 0.47
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4493775 0.87 RXFP1 (0.56) RXFP1KDM4EHSD17B10TAS1R3TAS1R1
SCHEMBL12276689 0.85 GPR35 (0.52) RXFP1KDM4EHSD17B10TAS1R3TAS1R1
SCHEMBL16926480 0.85 NPC1 (0.55) RXFP1KDM4EHSD17B10TAS1R3TAS1R1
SCHEMBL986276 0.81 TP53 (0.46) TAS1R3TAS1R1TAS1R2GAANPC1
SCHEMBL985881 0.80 LRRK2 (0.53) NPC1ALDH1A1THRBRAB9AMAPT
SCHEMBL29395986 0.79 MAPT (0.56) RXFP1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL4493780 0.79 MAPT (0.56) RXFP1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL32670789 0.79 MAPT (0.56) RXFP1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL985376 0.79 TP53 (0.46) GAAMAPTHPGDTP53
SCHEMBL5746185 0.77 MAPT (0.45) KDM4EHSD17B10GAANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937682-B1 MET KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
US-7547782-B2 Met kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-16 US disclosed
US-7547782-B2 Met kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-16 US disclosed
US-7547782-B2 Met kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-16 US disclosed
WO-2007041379-A1 MET KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-12 WO disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078140-A1 MET kinase inhibitors MET, ABL1, ERBB2 RXFP1 3559/4885KDM4E 592/4885HSD17B10 2762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.